Date: 2016-07-11
Type of information: Nomination
Compound:
Company: Avexis (USA - IL)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 11, 2016, AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced the appointment of Michael B. Johannesen to the executive management team as Senior Vice President, General Counsel and Chief Compliance Officer. Mr. Johannesen brings to AveXis nearly 20 years of legal experience within the global pharmaceutical, medical device and healthcare products industries, and is responsible for all aspects of the company’s legal and compliance functions, as well as human resources. Johannesen will report to Sean P. Nolan, President and CEO of AveXis. Mr. Johannesen has served as Vice President and Associate General Counsel at Hospira, where he was responsible for the commercial and compliance functions of Hospira’s legal department. Prior to joining Hospira, Mr. Johannesen worked as an attorney in the legal departments of Abbott Laboratories and Whirlpool Corporation. Mr. Johannesen began his legal career at Winston & Strawn in Chicago.
Financial terms:
Latest news:
